13F filer · CIK 1703031
Bain Capital Life Sciences Investors, LLC
Boston, MA · filing since Q4 2017 · last filing Aug 14, 2026
Reported value
$1.7B
+$573.2M vs prior
Positions
21
New / sold out
2 / 1
Added / reduced
2 / 7
Turnover
15.5%
buys $651.2M · sells $217.0M
Top-10 weight
87.9%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | KAILERA THERAPEUTICS INC | +22,583,268 | – | +$497.5M |
| Added | ALKERMES PLC | +1,327,938 | +217.7% | +$69.6M |
| New | HEMAB THERAPEUTICS HOLDINGS INC | +1,650,000 | – | +$60.6M |
| Added | CABALETTA BIO INC | +7,564,320 | +78.2% | +$23.5M |
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | NEWAMSTERDAM PHARMA COMPANY | -3,500,000 | -47.9% | $-118.6M |
| Reduced | HEARTFLOW INC | -2,000,000 | -19.1% | $-58.7M |
| Sold out | CENTESSA PHARMACEUTICALS | -635,000 | -100.0% | $-25.2M |
| Reduced | OLEMA PHARMACEUTICALS INC | -387,989 | -5.2% | $-4.9M |
| Reduced | ANNEXON INC | -774,943 | -14.9% | $-4.4M |
| Reduced | KYVERNA THERAPEUTICS INC | -225,000 | -7.2% | $-2.0M |
| Reduced | UPSTREAM BIO INC | -266,262 | -30.7% | $-1.8M |
| Reduced | ATEA PHARMACEUTICALS INC | -284,999 | -12.1% | $-1.3M |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | KAILERA THERAPEUTICS INCCOMMON STOCK | 22,583,268 | $497.5M | 29.58% |
| 2 | HEARTFLOW INCCOM | 8,448,158 | $247.9M | 14.74% |
| 3 | NEWAMSTERDAM PHARMA COMPANYORDINARY SHARES | 3,806,566 | $129.0M | 7.67% |
| 4 | SAVARA INCCOM | 17,600,621 | $108.4M | 6.45% |
| 5 | ALKERMES PLCSHS | 1,937,938 | $101.5M | 6.04% |
| 6 | SOLID BIOSCIENCES INCCOM NEW | 9,808,819 | $98.0M | 5.83% |
| 7 | PHARVARIS N VCOM | 2,675,509 | $92.5M | 5.50% |
| 8 | OLEMA PHARMACEUTICALS INCCOM | 7,085,249 | $88.6M | 5.27% |
| 9 | HEMAB THERAPEUTICS HOLDINGS INCCOM SHS | 1,650,000 | $60.6M | 3.60% |
| 10 | CABALETTA BIO INCCOM | 17,241,445 | $53.6M | 3.19% |
11 more rows. Subscribe for $29/month to see every row, download the data and use the API.